Hepatitis C treatment study for pregnant women
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 45 years old and between 14 and 32 weeks pregnant.
- You have hepatitis C (confirmed by a blood test).
- You have not had hepatitis C treatment before.
- You do not have hepatitis B or certain liver problems like severe cirrhosis.
- If you have HIV, your viral load is suppressed and you are on an HIV medicine that does not conflict with the study drug.
- You are willing to stay near the study site during pregnancy and for 10 weeks after giving birth (or 20 weeks after starting the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether treating hepatitis C during pregnancy is feasible and acceptable for pregnant women who have a history of drug use. If you qualify, you may receive treatment that could help protect your health and your baby's health.
This study is a pregnancy registry that collects information about people who have hepatitis C during pregnancy and took hepatitis C medicines early in pregnancy. It aims to better understand the safety and outcomes of treatment around conception.
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
This trial studies point-of-care (on-site) testing to find hepatitis C in adults who are at higher risk. If hepatitis C is found, earlier detection can help you get connected to care sooner.
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
Hear when a new Hepatitis C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.